CN105452265B - 用于治疗肿瘤性疾病尤其具有高her2蛋白水平的肿瘤性疾病的他莫昔芬衍生物 - Google Patents

用于治疗肿瘤性疾病尤其具有高her2蛋白水平的肿瘤性疾病的他莫昔芬衍生物 Download PDF

Info

Publication number
CN105452265B
CN105452265B CN201480033316.9A CN201480033316A CN105452265B CN 105452265 B CN105452265 B CN 105452265B CN 201480033316 A CN201480033316 A CN 201480033316A CN 105452265 B CN105452265 B CN 105452265B
Authority
CN
China
Prior art keywords
general formula
tamoxifen
derivatives
mitochondria
isomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480033316.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105452265A (zh
Inventor
伊里·纽齐尔
J·什图尔萨
L·维尔纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUZIL JIRI
Smart Brain sro
Springboard Investment Co
INSTITUTE OF BIOTECHNOLOGY
Original Assignee
Kkcg Co ltd
Kkcg Se
Smart Brain sro
INSTITUTE OF BIOTECHNOLOGY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50677895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105452265(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CZ2013-308A external-priority patent/CZ2013308A3/cs
Priority claimed from CZ2014-66A external-priority patent/CZ305571B6/cs
Application filed by Kkcg Co ltd, Kkcg Se, Smart Brain sro, INSTITUTE OF BIOTECHNOLOGY filed Critical Kkcg Co ltd
Publication of CN105452265A publication Critical patent/CN105452265A/zh
Application granted granted Critical
Publication of CN105452265B publication Critical patent/CN105452265B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5449—Polyphosphonium compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C09B23/0025—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being bound through an oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/14—Styryl dyes
    • C09B23/141—Bis styryl dyes containing two radicals C6H5-CH=CH-
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/008—Dyes containing a substituent, which contains a silicium atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
CN201480033316.9A 2013-04-24 2014-04-07 用于治疗肿瘤性疾病尤其具有高her2蛋白水平的肿瘤性疾病的他莫昔芬衍生物 Expired - Fee Related CN105452265B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CZ2013-308A CZ2013308A3 (cs) 2013-04-24 2013-04-24 Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2
CZPV2013-308 2013-04-24
CZ2014-66A CZ305571B6 (cs) 2014-01-29 2014-01-29 Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2
CZPV2014-66 2014-01-29
PCT/CZ2014/000035 WO2014173374A1 (en) 2013-04-24 2014-04-07 Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level

Publications (2)

Publication Number Publication Date
CN105452265A CN105452265A (zh) 2016-03-30
CN105452265B true CN105452265B (zh) 2017-05-10

Family

ID=50677895

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480033316.9A Expired - Fee Related CN105452265B (zh) 2013-04-24 2014-04-07 用于治疗肿瘤性疾病尤其具有高her2蛋白水平的肿瘤性疾病的他莫昔芬衍生物

Country Status (21)

Country Link
US (1) US9896466B2 (cg-RX-API-DMAC10.html)
EP (1) EP2989110B1 (cg-RX-API-DMAC10.html)
JP (1) JP6375091B2 (cg-RX-API-DMAC10.html)
KR (1) KR101764991B1 (cg-RX-API-DMAC10.html)
CN (1) CN105452265B (cg-RX-API-DMAC10.html)
AU (1) AU2014256546B2 (cg-RX-API-DMAC10.html)
CA (1) CA2909994C (cg-RX-API-DMAC10.html)
CY (1) CY1120821T1 (cg-RX-API-DMAC10.html)
DK (1) DK2989110T3 (cg-RX-API-DMAC10.html)
EA (1) EA029881B1 (cg-RX-API-DMAC10.html)
ES (1) ES2699099T3 (cg-RX-API-DMAC10.html)
GE (2) GEAP201813996A (cg-RX-API-DMAC10.html)
HR (1) HRP20181872T1 (cg-RX-API-DMAC10.html)
HU (1) HUE042239T2 (cg-RX-API-DMAC10.html)
MD (1) MD4626C1 (cg-RX-API-DMAC10.html)
NZ (1) NZ713589A (cg-RX-API-DMAC10.html)
PL (1) PL2989110T3 (cg-RX-API-DMAC10.html)
PT (1) PT2989110T (cg-RX-API-DMAC10.html)
SI (1) SI2989110T1 (cg-RX-API-DMAC10.html)
UA (1) UA116469C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014173374A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10548318B2 (en) * 2015-07-03 2020-02-04 Bayer Cropscience Aktiengesellschaft N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamide derivatives with herbicidal action
CN107709317B (zh) * 2015-07-03 2021-05-11 拜耳作物科学股份公司 具有除草作用的n-(1,3,4-噁二唑-2-基)芳基甲酰胺衍生物
HK1257296A1 (zh) * 2016-07-12 2019-10-18 Accutar Biotechnology Inc. 新的化合物及其用途
EP3484463B1 (en) 2016-08-19 2020-02-12 The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
EP3330274A1 (en) * 2016-12-01 2018-06-06 Springtide Ventures s.r.o. Compounds for treatment of senescence-related disorders
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
WO2019083997A1 (en) 2017-10-24 2019-05-02 Lunella Biotech, Inc. MITOFLAVOSCINS: TARGETING FLAVIN-CONTAINING ENZYMES THAT REMOVE CANCER STEM CELLS (CSC) BY INHIBITING MITOCHONDRIAL BREATHING
CR20200238A (es) 2017-11-24 2020-12-04 Lunella Biotech Inc Compuestos derivados de trifenilfosfonio para erradicar células madre cancerosas
CA3083487A1 (en) 2017-12-01 2019-06-06 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
US11541120B2 (en) 2017-12-05 2023-01-03 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
US11559527B2 (en) 2017-12-20 2023-01-24 Lunella Biotech, Inc. Targeting mitochondrial fission through mDIVI-1 derivatives
US20220211728A1 (en) * 2019-04-16 2022-07-07 Lunella Biotech, Inc. Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments
EP3753944A1 (en) 2019-06-17 2020-12-23 Institute Of Biotechnology Cas, V.V.I. 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006068A1 (en) * 1990-10-01 1992-04-16 Board Of Regents, The University Of Texas System High affinity tamoxifen derivatives and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3635708B2 (ja) * 1995-03-06 2005-04-06 出光興産株式会社 有機エレクトロルミネッセンス素子
TWI309571B (en) * 2002-12-31 2009-05-11 Ind Tech Res Inst Delivery carrier for targeting cells haring over-expressed estrogen
KR101003960B1 (ko) * 2003-08-22 2010-12-30 안티포딘 파마슈티칼스, 인코포레이티드 미토콘드리아 표적화 산화방지제로서 사용되는 미토퀴논 유도체를 포함하는 약제학적 조성물
AU2005261654A1 (en) * 2004-07-13 2006-01-19 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers
KR101642157B1 (ko) * 2008-03-14 2016-07-22 스티븐 존 랄프 미토콘드리아로 전달되는 항암 화합물
WO2010121177A2 (en) * 2009-04-17 2010-10-21 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
WO2011129837A1 (en) * 2010-04-16 2011-10-20 Olema Pharmaceuticals, Inc. Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006068A1 (en) * 1990-10-01 1992-04-16 Board Of Regents, The University Of Texas System High affinity tamoxifen derivatives and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Delivery of bioactive molecules to mitochondria in vivo;Robin A. J. Smith，et al.;《PNAS》;20030429;第100卷(第9期);5407-5412 *
Tamoxifen and Estradiol Interact with the Flavin Mononucleotide Site of Complex I Leading to Mitochondrial Failure;Paula I. Moreira，et al.;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20060112;第281卷(第15期);10143-10152 *

Also Published As

Publication number Publication date
NZ713589A (en) 2017-12-22
PL2989110T3 (pl) 2019-03-29
AU2014256546A1 (en) 2015-11-12
EA029881B1 (ru) 2018-05-31
HRP20181872T1 (hr) 2019-02-08
GEAP201813996A (en) 2018-03-12
MD20150117A2 (ro) 2016-08-31
CY1120821T1 (el) 2019-12-11
EP2989110A1 (en) 2016-03-02
KR101764991B1 (ko) 2017-08-10
CN105452265A (zh) 2016-03-30
EA201591918A1 (ru) 2016-02-29
US20160075726A1 (en) 2016-03-17
HK1216317A1 (zh) 2016-11-04
EP2989110B1 (en) 2018-08-08
KR20150144756A (ko) 2015-12-28
SI2989110T1 (sl) 2019-01-31
MD4626C1 (ro) 2019-11-30
JP2016522179A (ja) 2016-07-28
ES2699099T3 (es) 2019-02-07
GEP20186868B (en) 2018-06-25
PT2989110T (pt) 2018-11-15
DK2989110T3 (en) 2018-12-03
CA2909994A1 (en) 2014-10-30
US9896466B2 (en) 2018-02-20
JP6375091B2 (ja) 2018-08-15
WO2014173374A1 (en) 2014-10-30
AU2014256546B2 (en) 2017-03-30
HUE042239T2 (hu) 2019-06-28
MD4626B1 (ro) 2019-04-30
UA116469C2 (uk) 2018-03-26
CA2909994C (en) 2018-06-26

Similar Documents

Publication Publication Date Title
KR101764991B1 (ko) 특히 높은 her2 단백질 농도를 갖는 신생물성 질환의 치료를 위한 타목시펜 유도체
Burmaoglu et al. Synthesis, biological evaluation and molecular docking studies of bis-chalcone derivatives as xanthine oxidase inhibitors and anticancer agents
Snegur et al. Ferrocenylalkyl azoles: bioactivity, synthesis, structure
Jaouen et al. Ferrocifen type anti cancer drugs
Huang et al. Combretastatin A-4 analogue: a dual-targeting and tubulin inhibitor containing antitumor Pt (IV) moiety with a unique mode of action
Panchangam et al. Antitumor effects of Ir (III)-2 H-indazole complexes for triple negative breast cancer
Ribeiro et al. Ruthenium (II) Phosphine/Mercapto complexes: their in vitro cytotoxicity evaluation and actions as inhibitors of topoisomerase and proteasome acting as possible triggers of cell death induction
Štarha et al. Platinum (II) iodido complexes of 7-azaindoles with significant antiproliferative effects: an old story revisited with unexpected outcomes
WO2021212691A1 (zh) 一种线粒体靶向化合物及其制备方法和应用
Singh et al. A family of silatrane‐armed triazole‐encapped salicylaldehyde‐derived Schiff bases: Synthesis, spectral analysis, and antimicrobial and quantum chemical evaluation
Alexander et al. Dinuclear platinum (II) complexes of imidazophenanthroline-based bridging ligands as potential anticancer agents: synthesis, characterization, and in vitro cytotoxicity studies
Liu et al. Design and biological features of platinum (II) complexes with 3-hydroxy-3-(Trifluoromethyl) cyclobutane-1, 1-Dicarboxylate as a leaving ligand
EP2924044A1 (en) Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
CN102627685B (zh) 一氧化氮供体型谷胱甘肽类化合物、其制备方法及医药用途
CA3045365C (en) Compounds for treatment of senescence-related disorders
CN110156822A (zh) 一种萘酚-苯硼酸类化合物及其制备方法和用途
Özdaş et al. Targeting of nucleo‑cytoplasmic transport factor exportin 1 in malignancy
CN103214422A (zh) 一类新型取代胺基咪唑酮衍生物的制备方法及抗癌作用
CN108727451B (zh) 新的磷化烃金化合物及其制备方法和应用
HK1216317B (en) Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
Wang et al. Synthesis, cytotoxicity and anti‐metastatic properties of new pyridyl–thiazole arene ruthenium (II) complexes
CZ304553B6 (cs) Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2
CZ305571B6 (cs) Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2
Limarev et al. Stepwise preparation, structure, and in vitro biotestings of the monoribbed-heterodifunctionalized bis-α-benzildioximate iron (II) clathrochelates with two terminal biorelevant groups as potential cytotoxic agents
BR112020015745A2 (pt) Conjugados de fármacos de moléculas pequenas de monofosfato de gemcitabina

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Prague

Applicant after: SMART BRAIN S.R.O.

Applicant after: Institute of Biotechnology

Applicant after: NEUZIL JIRI

Applicant after: KKCG Limited by Share Ltd.

Address before: Prague

Applicant before: SMART BRAIN S.R.O.

Applicant before: Institute of Biotechnology

Applicant before: NEUZIL JIRI

Applicant before: KKCG SE

COR Change of bibliographic data
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1216317

Country of ref document: HK

CB02 Change of applicant information

Address after: Prague

Applicant after: SMART BRAIN S.R.O.

Applicant after: Institute of Biotechnology

Applicant after: NEUZIL JIRI

Applicant after: KKCG CO.,LTD.

Address before: Prague

Applicant before: SMART BRAIN S.R.O.

Applicant before: Institute of Biotechnology

Applicant before: NEUZIL JIRI

Applicant before: KKCG Limited by Share Ltd.

COR Change of bibliographic data
GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1216317

Country of ref document: HK

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210106

Address after: Prague

Patentee after: SMART BRAIN S.R.O.

Patentee after: Institute of Biotechnology

Patentee after: NEUZIL JIRI

Patentee after: Springboard Investment Co.

Address before: Prague

Patentee before: SMART BRAIN S.R.O.

Patentee before: Institute of Biotechnology

Patentee before: NEUZIL JIRI

Patentee before: KKCG CO.,LTD.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170510